Autologous reconstitution is a major problem after cord blood transplant (CBT) for patients with hemoglobinopathies (Hbpathies). We analyzed risk factors for neutrophil engraftment in 31 patients with Hbpathies (Sickle cell disease (SCO) n=6, and Thalassemia (Thai) n=25) receiving a related CBT in 15 transplant centers. All CB donors were HLJA matched, except one (1 HLA-A difference). Median recipient age was 5 years (1-19) and median follow-up was 24 months (2-72). At transplant, 19 and 12 patients belonged :o class 1 and class 2 of the Pesaro classification, respectively. One patient with SCO had previously had stroke. As preparative regimen, 17 patients received Cyclophosphamic e (CY) associated to Busulfan (BU) and 14 patients were given CY+BU associated Thiotepa (THIO) (n=9) or Fludarabine (FLU) (n=5). ATG was associated in 12 cases. GVHD prophylaxis consisted of either Cyclosporine A (CsA) alone (n=23) or associated to Methotrexate in 8 cases. Median number of nucleated cells infused was 3.8 x lOVl.g (1.2-10). Prophylactic hematopoietic growth factors (
Influence of preparative regimen and methotrexate for GVHD prophylaxis on engraftment after related cord blood transplant for patients with hemoglobinopathies. An eurocord group analysis / Locatelli, F.; Rocha, V.; Ertem, M.; Graphacos, S.; Bernaudin, F.; Li, X.; Brichard, B.; Nagler, A.; Miniero, R.; Roberts, I.; Yaniv, I.; Lutz, P.; Will, A.; Raja, T.; Garnier, F.; Gluckman, E.. - In: BLOOD. - ISSN 0006-4971. - 96:11(2000), p. 200.
Influence of preparative regimen and methotrexate for GVHD prophylaxis on engraftment after related cord blood transplant for patients with hemoglobinopathies. An eurocord group analysis
Locatelli F.;
2000
Abstract
Autologous reconstitution is a major problem after cord blood transplant (CBT) for patients with hemoglobinopathies (Hbpathies). We analyzed risk factors for neutrophil engraftment in 31 patients with Hbpathies (Sickle cell disease (SCO) n=6, and Thalassemia (Thai) n=25) receiving a related CBT in 15 transplant centers. All CB donors were HLJA matched, except one (1 HLA-A difference). Median recipient age was 5 years (1-19) and median follow-up was 24 months (2-72). At transplant, 19 and 12 patients belonged :o class 1 and class 2 of the Pesaro classification, respectively. One patient with SCO had previously had stroke. As preparative regimen, 17 patients received Cyclophosphamic e (CY) associated to Busulfan (BU) and 14 patients were given CY+BU associated Thiotepa (THIO) (n=9) or Fludarabine (FLU) (n=5). ATG was associated in 12 cases. GVHD prophylaxis consisted of either Cyclosporine A (CsA) alone (n=23) or associated to Methotrexate in 8 cases. Median number of nucleated cells infused was 3.8 x lOVl.g (1.2-10). Prophylactic hematopoietic growth factors (I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.